Causeway Bay, HK – October 22, 2025 – PRESSADVANTAGE –
Ginza Diamond Shiraishi Hong Kong announces the continuation of its longstanding dedication to precision, artistry, and design in the creation of 結婚戒指 (wedding rings). With a heritage deeply rooted in fine jewelry craftsmanship, the brand’s Hong Kong presence reflects an enduring commitment to providing couples with rings that embody both aesthetic refinement and symbolic significance.
Ginza Diamond Shiraishi has consistently emphasized the connection between timeless design and the personal meaning of marriage. Each wedding ring is designed with careful attention to balance, comfort, and durability—ensuring that the piece represents not only the beauty of craftsmanship but also the enduring bond it symbolizes.
At the core of Ginza Diamond Shiraishi’s design philosophy is the concept of harmony. The company’s designers and craftsmen focus on achieving a precise equilibrium between form and function, resulting in wedding rings that combine graceful contours with practical wearability. This balance allows each ring to serve as both a daily adornment and a lifelong keepsake. The attention to fine detail—from diamond setting to band curvature—is integral to the overall experience of wearing the ring.
Ginza Diamond Shiraishi’s diamond selection process reflects stringent quality standards. Each diamond undergoes an evaluation based on the internationally recognized “Four Cs”—cut, color, clarity, and carat weight. These standards ensure that every diamond used in a Ginza Diamond Shiraishi wedding ring meets the expectations of excellence and consistency. The brand also places importance on transparency and traceability, reflecting the broader jewelry industry’s growing attention to ethical sourcing and consumer trust.
Ginza Diamond Shiraishi Hong Kong has aligned its operations with this global standard, emphasizing craftsmanship rooted in responsible practices. The company maintains close relationships with trusted suppliers and certified gemological partners, ensuring that materials used in its wedding rings are sourced with care and integrity. This approach not only guarantees quality but also supports the long-term sustainability of fine jewelry production.
Technological precision also plays a significant role in the creation of Ginza Diamond Shiraishi wedding rings. Modern tools such as high-accuracy casting systems, digital modeling, and microscopic diamond setting ensure that each ring achieves exacting standards of finish and structure. These technologies, combined with human craftsmanship, produce a seamless result—one where artistry and innovation coexist. The goal is to achieve perfection not only in visual form but in how the ring feels when worn.
In Hong Kong, where traditions blend with contemporary lifestyle influences, the symbolism of the wedding ring (結婚戒指) continues to hold deep cultural resonance. Ginza Diamond Shiraishi recognizes this duality and designs its rings to suit diverse expectations—some couples value understated elegance, while others prefer designs that reflect individuality or family heritage. The brand’s artisans work to accommodate both, creating wedding rings that are versatile in design yet consistent in quality.
Another hallmark of Ginza Diamond Shiraishi’s approach is its emphasis on personal consultation. The process of selecting a wedding ring often includes detailed discussions about design options, ring fit, and diamond selection. Each element is explained in detail to ensure that the couple understands the craftsmanship and materials involved. This transparent and educational approach has contributed to the brand’s longstanding reputation for reliability within the bridal jewelry sector.
Cultural symbolism remains an integral part of the design process. Many of the brand’s wedding ring collections feature motifs inspired by nature, balance, and the cyclical nature of time. Rings are crafted with smooth inner surfaces for comfort, while outer details—such as gentle curves, engravings, or subtle diamond placements—express the continuity of love and commitment. The interplay between simplicity and sophistication defines much of Ginza Diamond Shiraishi’s work, appealing to those who value quiet elegance over excess ornamentation.
The company’s continued investment in craftsmanship training ensures that skills are passed on to new generations of artisans. Precision techniques, such as hand-polishing and setting, are still central to production even as the brand incorporates digital design tools. This combination of tradition and technology underscores Ginza Diamond Shiraishi’s philosophy that true craftsmanship evolves without losing its foundational artistry.
In Hong Kong’s dynamic bridal jewelry market, Ginza Diamond Shiraishi serves as a representative of craftsmanship that values authenticity and care. While design trends may evolve, the brand’s commitment to its guiding principles—refinement, precision, and emotional connection—remains unchanged. Its approach reflects an understanding that a wedding ring is not merely a decorative accessory but a meaningful artifact that records one of life’s most important commitments.
By emphasizing integrity in sourcing, meticulous craftsmanship, and timeless design, Ginza Diamond Shiraishi continues to contribute to the global standard for wedding rings (結婚戒指). The Hong Kong boutique’s operations mirror the brand’s heritage of combining artistry with quality assurance, ensuring that each piece upholds both technical excellence and emotional value.
This continued dedication to fine jewelry craftsmanship reinforces Ginza Diamond Shiraishi’s place among the leading names in bridal jewelry. The wedding ring, as interpreted through the brand’s design ethos, stands as a testament to enduring craftsmanship—a tradition that celebrates not only the artistry of creation but the promise it represents between two people.
For more information about Ginza Diamond Shiraishi Causeway Bay 銀座白石銅鑼灣, contact the company here:
Ginza Diamond Shiraishi Causeway Bay 銀座白石銅鑼灣 Mr. Shiraishi (852) 2787 0606 admin@diamond-shiraishi.hk Shop G29-30, Fashion Walk, 11-19 Great George Street, Causeway Bay, Hong Kong
HAMPSTEAD, NH – October 22, 2025 – PRESSADVANTAGE –
KTM Exteriors & Roofing, a family-owned exterior services company serving the Greater Boston area for over 40 years, is reminding property owners about the critical importance of winter roof inspections as New England experiences increasingly unpredictable weather patterns this season.
With recent temperature fluctuations causing repeated freeze-thaw cycles throughout the Boston metropolitan area, roofs face heightened stress that can lead to damage if left unaddressed. The company reports seeing increased demand for inspection services as property owners recognize the value of preventative maintenance during challenging weather conditions.
“Winter weather in New England presents unique challenges for both residential and commercial roofing systems,” said a representative of KTM. “Ice dams, snow accumulation, and rapid temperature changes can all contribute to roof deterioration. Regular inspections help identify potential issues before they become costly repairs, especially given the architectural diversity and varying building codes across Boston’s neighborhoods.”
The company’s inspection services cover comprehensive evaluations of roofing materials, flashing, gutters, and other exterior components that work together to protect properties from the elements. Their team examines shingle integrity, checks for proper ventilation, and assesses areas prone to ice dam formation, providing detailed reports to property owners.
As a roofing contractor Boston residents have relied on for four decades, the company brings extensive experience with various roofing materials, including asphalt, rubber, and specialty shingle designs. This expertise proves particularly valuable when evaluating how different materials respond to New England’s harsh winter conditions.
The importance of professional inspections extends beyond immediate damage prevention. Regular maintenance can significantly extend roof lifespan, improve energy efficiency, and maintain property values. For commercial properties, proper roof maintenance also ensures compliance with local building codes and insurance requirements.
“Property owners often underestimate how much damage can occur during winter months,” the representative continued. “Small issues like loose shingles or minor flashing gaps can quickly escalate when exposed to snow, ice, and freezing temperatures. Our inspection services help identify these vulnerabilities early, allowing for timely repairs that prevent more extensive damage.”
The company’s approach to winter inspections includes thorough documentation of current roof conditions, identification of potential problem areas, and recommendations for necessary repairs or maintenance. Their team also provides guidance on preventative measures property owners can take to minimize winter-related roof stress.
KTM Exteriors & Roofing is a full-service exterior contractor specializing in roofing, siding, windows, and related services for residential and commercial properties throughout the Greater Boston area. The woman-owned business maintains full licensing and insurance while offering comprehensive warranties on workmanship and materials. Their services encompass installation, replacement, repair, and maintenance of roofing systems, along with additional exterior services including window installation, siding, and gutter cleaning. The company has built its reputation on quality craftsmanship, transparent communication, and deep knowledge of local architectural styles and building requirements.
###
For more information about KTM Exteriors & Roofing, contact the company here:
SAN BERNARDINO, CALIFORNIA / ACCESS Newswire / October 27, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) (Dateline or the Company) is pleased to provide an update on the drilling activities underway at its 100%-owned Colosseum Gold-REE Project in California, USA.
Three drill rigs are currently operating on site, one diamond rig and two reverse circulation (RC) rigs and until recently, the program was supported by an additional sonic rig that has now completed its tailings stability work and has been demobilised.
The current drilling phase is focused on compact infill, extensional, geotechnical, and tailings stability holes as part of the Bankable Feasibility Study (BFS). The broader program will shortly transition to testing several newly defined, high-priority gold and rare earth targets identified from recent geophysical and geochemical work across the Colosseum system.
Highlights
BFS Drilling: The compact BFS drill program of 32 holes for 4,257 metres (13,968 feet) is 67% complete with an estimated end date of November 7, 2025.
Stockpile Drilling: Approximately 1Mt of historical stockpiles grading ~1 g/t Au will be RC drilled to confirm grade continuity and support inclusion in the mine plan, potentially adding already mined ~30,000oz of gold to the feasibility inventory.
Tailings Stability Drilling: A sonic drilling program over the existing tailings storage facility was completed, confirming the foundation is stable and suitable for additional lifts as part of the planned development.
Exploration Targets: The major phase of the drilling campaign will focus on newly defined gold and rare earth targets, with both programs to be drilled concurrently. Drilling will begin on the high-priority gold breccia pipe targets (Targets 1, 5 and 6) alongside the 2200N REE target, the first of three defined anomalies to be tested.
Dateline’s Managing Director, Stephen Baghdadi, commented:“Having multiple rigs on site has allowed us to accelerate the program so we can focus our efforts sooner on the new gold and rare earth targets. With over 1,400 samples already at the lab, we look forward to reporting the results as they become available and are analysed.
“Our geology team is eager to commence drilling the new gold and REE targets in early November.”
BFS Drill Program Status
Infill and Extensional Program
The Scoping Study outlined 16.6 Mt of ore, with 81% classified as Measured and Indicated and the remaining 19% as Inferred. The current drill program is designed to infill these Inferred areas and support upgrades to Indicated or Measured categories, providing greater confidence in mine scheduling and production planning.
The infill component comprises 32 holes for 4,257 metres (13,968 feet) and is now 67% complete. Samples from the completed holes have been dispatched to ALS Reno for analysis.
Figure 1: RC rig infill drilling the North Pipe at Colosseum
Stockpile Drilling
When Dateline acquired the Colosseum Project in 2021, it inherited an existing ore stockpile left on site following the suspension of operations in 1993. Historical mine records indicate the stockpile contains approximately 1Mt grading 1.0 g/t Au for an estimated 30,000 ounces of gold.
To date, Dateline’s work has focused on expanding the in-situ Mineral Resource, and the stockpile has not yet been drilled or included in the current mine plan. The Company now intends to complete reverse-circulation (RC) drilling to confirm the tonnes and grade of this material, enabling it to be incorporated into the development schedule.
This mined stockpile has the potential to be processed during the commissioning phase of the operation, providing an early source of mill feed, accelerating gold production, and enhancing overall project economics.
Figure 2: Stockpiles to be assessed with RC drilling
Tailings Stability Drilling
Dateline plans to reutilise the existing tailings storage facility (TSF) at Colosseum as part of the proposed mine development. The design involves filter pressing the tailings prior to deposition, allowing the material to be stacked dry on top of the existing facility. This approach enables water recirculation, significantly reducing overall water consumption and supporting construction of additional TSF lifts.
To confirm the suitability of this approach, a program of sonic drilling was completed across the TSF site. The recovered core was reviewed by the Company’s hydrogeological consultants, who have provided their findings to the BFS team. Results confirmed the foundation stability and suitability of the existing TSF for future use as a dry-stack tailings and waste rock facility.
Figure 3: Sonic drill rig on site at the Colosseum TSF
Figure 4: Existing TSF area drilled with sonic drilling
New Target Drilling
The BFS drilling programs were prioritised for completion ahead of the new target testing, as they form part of the critical path for the Colosseum development timeline. With these programs now nearing completion, the focus is shifting to the next phase of drilling-testing the newly defined gold and rare earth element (REE) targets.
Dateline has ranked several high-priority targets for initial assessment, with Gold Targets 1, 5 and 6 and REE Target 2200N to be drilled first as part of the expanded exploration campaign.
Figure 5: New Target Drilling with gold targets 1, 5 and 6 and REE target 2200N shown
This ASX announcement has been authorised for release by the Board of Dateline Resources Limited.
Dateline Resources Limited (ASX: DTR, OTCQB: DTREF, FSE: YE1) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.
The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.
On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.
The Colosseum is located less than 10km north of the Mountain Pass Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.
Dateline has also acquired the high-grade Argos Strontium Project, also located in San Bernadino County, California. Argos is reportedly the largest strontium deposit in the U.S. with previous celestite production grading 95%+ SrSO4.
Forward-Looking Statements
This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behaviour of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.
Competent Person Statement
Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.
Company Confirmations
The Company confirms it is not aware of any new information or data that materially affects the information included in the announcements dated 23 October 2024 with regard to the Colosseum MRE and 23 May 2025 with regard to Colosseum Project Economics. Similarly, the Company confirms that all material assumptions and technical parameters underpinning the estimates and the forecast financial information referred to in those previous announcements continue to apply and have not materially changed.
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo
Updated ANTHEM-UC data support Phase 3 clinical development of icotrokinra in both moderately to severely active ulcerative colitis and Crohn’s disease
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study
Further, 67% of patients treated with icotrokinra in the ICONIC-TOTAL study achieved overall rates of clear or almost clear skin by Week 24, which was maintained through Week 52
NEWARK, CALIFORNIA / ACCESS Newswire / October 27, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced new data from two studies of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, presented at two recent medical conferences.
Week 28 data from the Phase 2b ANTHEM-UC study of icotrokinra will be presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG), demonstrating sustained and clinically meaningful results, with all doses (100 mg, 200 mg and 400 mg) showing higher rates of clinical response a , clinical remission b , endoscopic improvement c and histologic-endoscopic mucosal improvement (HEMI) d at Week 28 compared to placebo. [1] These outcomes build on Week 12 data that was recently presented at United European Gastroenterology (UEG) Week 2025.
Icotrokinra 400 mg once daily
Week 12
Week 28
Placebo (at Week 28)
Clinical response 1
63.5%
66.7%
25.4%
Clinical remission 1
30.2%
31.7%
9.5%
Endoscopic improvement 1
36.5%
38.1%
11.1%
HEMI rates 1
28.6%
33.1%
11.1%
Based on results from the Phase 2b ANTHEM-UC study, Johnson & Johnson has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC, as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderate to severely active Crohn’s disease.
Additionally, new long-term 52-week data from the Phase 3 ICONIC-TOTAL study e , presented last week at the 2025 Fall Clinical Dermatology Conference, show icotrokinra demonstrated high and durable rates of site-specific psoriasis clearance affecting these high-impact and difficult-to-treat areas of the body. [2]
72% of patients with scalp psoriasis achieved a scalp-specific Investigator’s Global Assessment (ss-IGA) 0/1 score and 57% achieved ss-IGA 0 f
85% of patients with genital psoriasis achieved a Physician’s Global Assessment of Genitalia (sPGA-G) 0/1 and 73% achieved sPGA-G 0 g
In the smaller subset of patients with hand/foot psoriasis, treatment with icotrokinra showed a numerically higher rate of skin clearance at Week 16, which increased through Week 52 with patients achieving a hand and/or foot Physician’s Global Assessment (hf-PGA) h score of 0/1 increasing from 42% to 62%.
Overall response rates among patients treated with once-daily icotrokinra were maintained through Week 52, with 67% of patients treated with icotrokinra achieving clear or almost clear skin (Investigator’s Global Assessment (IGA) i 0/1) and 44% achieving completely clear skin (IGA 0) at Week 52. The overall response rates were also comparable among patients who received icotrokinra for all 52 weeks and those who transitioned from placebo to icotrokinra at Week 16 (67% versus 68% achieved IGA0/1, respectively). Across treatment groups, adverse event and serious adverse event rates were similar through Week 52 compared to those through Week 16, with no new safety signals identified.
“Additional data from Phase 2b ANTHEM-UC and Phase 3 ICONIC-TOTAL studies continue to show a strong durability of response and clinical benefit of icotrokinra treatment in a range of inflammatory and immunological diseases,” said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. “We are very pleased to see that the ICONIC development program now includes both ICONIC-UC, a Phase 3 study in adults with moderately to severely active UC, and ICONIC-CD, a Phase 2b/3 study in adults with moderate to severely active Crohn’s disease. Our goal continues to be delivering well-differentiated oral targeted therapy treatments for patients as we continue to advance our oral peptides-based scientific and innovation leadership in the I&I field.”
Editor’s notes:
Clinical response was defined as a decrease from baseline in the modified Mayo score by greater than or equal to (>=) 30 percent (%) and >=2 points, with either a >=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.
Clinical remission was defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.
Endoscopic improvement was defined as an endoscopy subscore of 0 or 1.
Histologic-endoscopic mucosal improvement (HEMI) was defined as histologic remission (absence of neutrophils from the mucosa in both lamina propria and epithelium, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system) and endoscopic improvement (MES of 0 or 1).
ICONIC-TOTAL evaluates the efficacy and safety of icotrokinra compared with placebo in participants with at least moderate scalp, genital, and/or hand/foot PsO with once-daily icotrokinra or placebo, with placebo-to-icotrokinra transition at Week 16.
The ss-IGA is a five-point scale where scalp lesions are assessed in terms of clinical signs of redness, thickness, and scaliness on a severity score ranging from 0 to 4, where 0 indicates absence of disease, 1 is very mild, 2 is mild, 3 is moderate and 4 indicates severe disease.
The sPGA-G is a six-point scale used to evaluate the severity of genital psoriasis at a given time point ranging from 0 to 5, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, 4 is severe and 5 indicates very severe disease. [3]
The Physician’s Global Assessment of Psoriasis on the Hands and/or Feet (hf-PGA) assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3) and severe (4). [4]
The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, and 4 indicates severe disease. [5]
About ANTHEM-UC
ANTHEM-UC ( NCT06049017 ) is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab) and/or ozanimod or approved JAK inhibitors. The study is evaluating three once-daily dosages of icotrokinra taken orally. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.
About Ulcerative Colitis Ulcerative colitis (UC) is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus. It is the result of the immune system’s overactive response.Symptoms vary but may typically include loose and more urgent bowel movements, rectal bleeding or bloody stool, persistent diarrhea, abdominal pain, loss of appetite, weight loss, and fatigue.
About the ICONIC Clinical Development Program The pivotal Phase 3 ICONIC clinical development program of icotrokinra (JNJ-2113) in adult and pediatric patients 12 years of age and older with moderate-to-severe plaque PsO was initiated with two studies in Q4 2023 – ICONIC-LEAD and ICONIC-TOTAL – pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company.
ICONIC-LEAD ( NCT06095115 ) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary endpoints.
ICONIC-TOTAL ( NCT06095102 ) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.
Other Phase 3 studies in the development program include ICONIC-ADVANCE 1 ( NCT06143878 ) and ICONIC-ADVANCE 2 ( NCT06220604 ), which are evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO. ICONIC-ASCEND will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque psoriasis. ICONIC-PsA 1 ( NCT06878404 ) and ICONIC-PsA 2 ( NCT06807424 ) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants with active psoriatic arthritis.
Johnson & Johnson has also initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderate to severely active Crohn’s disease.
About Plaque Psoriasis Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease. Nearly one-quarter of all people with plaque PsO have cases that are considered moderate-to-severe.Plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales.Plaques may appear red in lighter skin or more of a purple, gray or dark brown color in patients with darker skin tones. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.Living with plaque PsO can be a challenge and impact life beyond a person’s physical health, including emotional health, relationships, and handling the stressors of life. Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that precisely blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/ .
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra, and expectations regarding the icotrokinra development program. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Johnson & Johnson and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
[1] Jairath V., et al. Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, In Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-ranging Trial. Poster 1066 at ACG Annual Scientific Meeting 2025. October 2025.
[2] Lain, E et al. Durability of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings. Oral presentation (Presentation FC01.1G) at the 2025 Fall Clinical Dermatology Conference. October 2025.
[3] Merola JF, Bleakman AP, Gottlieb AB, et al. The Static Physician’s Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol . 2017;16(8):793-799
[4] Goldblum O, et al. Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint. J Am Acad Dermatol. 2013:68(4)Supplement1:AB218.
[5] Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104. Accessed April 2025.
VANCOUVER, BC / ACCESS Newswire / October 27, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) (“Avino” or “the Company”) reports results of four additional drill holes from La Preciosa which were drilled to twin previous drilling. Assay results for the intercepts of the La Gloria and Abundancia veins continued to be very positive and are shown in Table 1. Previous drill results can be found here .
Selected Intercept Highlights:
Hole PMLP 25-06: 787 g/t Ag and 0.51 g/t Au over 5.22 metres true width
including 3,206 g/t Ag and 1.02 g/t Au over 0.77 metres true width
Hole PMLP 25-08 at Gloria: 306 g/t Ag and 1.15 g/t Au over 3.98 metres true width
including 699 g/t Ag and 5.80 g/t Au over 0.63 metres true width
Hole PMLP 25-08 at Abundancia: 463 g/t Ag and 0.61 g/t Au over 4.00 metres true width
including 642 g/t Ag and 0.60 g/t Au over 0.95 metres true width
Based on previous drill results, the variation of grades and thicknesses within relatively short distances (under 10 metres) compared with previously drilled intercepts were expected due to the “pinch and swell” geometry of the La Preciosa veins and the high nugget effects. The drill results exceeded grade expectations and verified the geometry of the current vein-based resource model.
“We’re excited to share continued strong results from four new drill holes at La Preciosa, each returning excellent grades that exceed the current resource average. These results reinforce the strategy of using underground mining methods to unlock the value of the deposit” said David Wolfin, President and CEO. “Notably, the wider intercepts at La Gloria and Abundancia highlight the deposit’s potential, especially early in the mine life. We’ll continue to refine our geological model, expand drilling into underexplored areas, and integrate ongoing channel sampling data as development advances on both veins, in both direction at level 3.”
Drilling Results
Assays were received on four holes totalling 915 metres drilled at La Preciosa, intersecting the La Gloria vein in all four holes, the Abundancia vein in three holes, and additional unnamed and splay veins in one of the holes. Assays were processed under Avino’s standard QA/QC program, with no indications of bias or contamination detected. Unlike the Avino Mine, the La Preciosa deposit contains no notable copper mineralization, so no copper values are reported.
Details are shown in the table and images below.
Table 1 – Summary Drill Results
Structure
Hole Number
From (m)
To (m)
Intercept Length (m)
True width (m)
Au (g/t)
Ag (g/t)
AgEq ¹ (g/t)
La Gloria
PMLP-25-05
223.25
226.45
3.2
2.48
0.66
425
484
Including
225.7
226.45
0.75
0.58
1.60
1299
1441
Abun Splay 1
PMLP-25-05
234.5
237.6
3.1
3.07
0.16
34
48
Abundancia
PMLP-25-05
303.75
304.55
0.8
0.78
1.21
513
621
Unnamed_5
PMLP-25-05
221.3
221.8
0.5
0.40
1.02
455
546
Unnamed_6
PMLP-25-05
261.71
263.06
1.35
0.90
0.29
74
100
La Gloria
PMLP-25-06
169.8
176.6
6.8
5.22
0.51
787
832
Including
174.45
175.45
1
0.77
1.02
3206
3297
Abundancia
PMLP-25-06
219.4
220.9
1.5
1.47
0.86
635
711
La Gloria
PMLP-25-07
175.9
181.7
5.8
2.84
0.39
216
251
Including
176.93
178
1.07
0.52
0.35
490
521
Abundancia
PMLP-25-07
227.2
227.75
0.55
0.52
0.24
93
114
La Gloria
PMLP-25-08
53.15
58.5
5.35
3.98
1.15
306
408
Including
53.15
54.00
0.85
0.63
5.80
699
1215
Abundancia
PMLP-25-08
135.60
139.80
4.20
4.00
0.61
463
517
Including
136.6
137.6
1
0.95
0.60
642
696
AgEq in drill results above assumes $4000/oz Au and $45.00/oz Ag, and 100% metallurgical recovery.
Figure 1 – Plan View of the La Gloria Vein Showing the Current Drill Hole Locations and the Twin Hole Locations as well as the Projected View of the Decline and Surface Works.
Figure 2 – Longitudinal View of the La Gloria Vein Showing the Current Holes (highlighted) Relative to the Historic Drilling.
Figure 3 – Longitudinal View of the Abundancia Vein Showing the Current Holes (highlighted) Relative to the Historic Drilling.
Figure 4 – Cross-Section of PMLP25-08, looking North, Showing the Abundancia Vein, the La Gloria vein and the Projections of the Decline Ramp.
Geological Description
La Preciosa deposit is situated on the eastern flank of the Cretaceous to mid-Tertiary Sierra Madre Occidental. The SMO is the largest silicic igneous province in North America, and it stretches from the USA-Mexico border to the latitude of Guadalajara, where the SMO is covered by the late Miocene to Quaternary Trans-Mexican Volcanic Belt.
Mineralization at the La Preciosa is hosted within multiple discrete poly-phase quartz veins, often displaying banded, smoky, drusy, and chalcedonic textures. Also, in each stage, there is variably crustiform banded fracture fill/breccia cement mineralogy. Fluorite, amethyst, a substantial number of barite laths, calcite, and rhodochrosite may also be present, and sulphide mineralization in the form of sphalerite, galena, pyrite, chalcopyrite, acanthite, sparse native silver, and free gold, as well as iron and manganese oxides have been noted in drill core. The principal silver-bearing mineral at the La Preciosa is acanthite-pseudomorphic after argentite or as microcrystalline to amorphous grains.
The main vein system on the Abundancia ridge consists of dominantly north-south-striking and westward-dipping veins plus east-southeast-striking, south-dipping crosscutting veins. The Abundancia vein system has been traced on the surface for over 1.5 km. In the eastern part of the Project, a north- to northwest-striking, shallow west-dipping vein system with associated hanging wall veining and alteration is exposed in a series of hills. This vein system is referred to as the Martha vein and has been traced by drilling for over 2.5 km along the strike.
The mineralization in the area occurs in veins, veinlets, and stockwork. These veins average in true width less than 15 m (Martha Vein) and consist of several stages of banded crustiform to colloform, quartz (and cryptocrystalline quartz at shallow depths), adularia, barite, and typically later carbonates (both calcite and rhodochrosite); illite commonly replaces the adularia. There are variable amounts of pyrite, sphalerite, and galena plus argentite, and variable amounts of tetrahedrite – tennantite, freibergite, and Ag sulfosalt.
There are steep-dipping veins in the west, such as the La Gloria vein. These steep veins can be considered as a mineralized zone or lode of stock work, silicification, breccias, veins, vein breccias, veinlets, and a general mix of multiple styles of mineralization.
The mineralization displays characteristics typical of epithermal veins in Mexico, particularly of the Ag-rich variety. Quartz veins are accompanied by adularia, barite, calcite, and rhodochrosite of variable timing, as well as acanthite, freibergite, Ag sulfosalts and minor electrum, plus variable amounts of pyrite, honey-coloured sphalerite, tennantite/tetrahedrite, chalcopyrite and galena, and supergene Fe and Mn oxides; the hypogene minerals are characteristic of intermediate-sulphidation deposits in Mexico. Mineralization is believed to be Tertiary in age, and both the Lower Volcanic Supergroup (LVS) and Upper Volcanic Supergroup (UVS) are mineralized, but the overlying basalts are recent and not mineralized.
Sampling and Assay Methods
Following detailed geological and geotechnical logging, selected drill core areas were cut in half. One half of the core was submitted to the SGS Laboratory facility in Durango, Mexico, and the other half was retained on-site for verification and reference. Gold is assayed by fire assay with an AA finish. Any samples exceeding 3.0 gold g/t are re-assayed and followed by a gravimetric finish. Multi-element analyses are also completed for each sample by SGS ICP14B methods. Silver is fire assayed with a gravimetric finish for samples assaying over 100 g/t. Avino uses a series of standard reference materials, blank reference materials, and duplicates as part of their QA/QC program during assaying.
Qualified Person(s)
Avino’s projects in Durango, Mexico are under the geoscientific oversight of Michael F. O’Brien, P.Geo., Senior Principal Consultant, Red Pennant Communications, and under the supervision of Peter Latta, P.Eng, Avino’s VP, Technical Services, who are both qualified persons within the context of NI 43-101. Both have reviewed and approved the technical data in this news release.
About Avino
Avino is a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company’s silver, gold and copper production remains unhedged. The Company intends to maintain long term sustainable and profitable mining operations to reward shareholders and the community alike through our growth at the historic Avino Property and the strategic acquisition of the adjacent La Preciosa which was finalized in Q1 2022. Early in 2024, the Pre-feasibility Study on the Oxide Tailings Project was completed. This study is a key milestone in our growth trajectory. Avino has been included in the Toronto Stock Exchange’s 2025 TSX30™. Avino has distinguished itself by reaching the 5th position on the TSX30 2025 ranking. As part of Avino’s commitment to adopting sustainable practices, we have been operating a dry-stack tailings facility for more than two years with excellent results. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on X (formerly Twitter) at @Avino_ASM and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.
Note: All Avino Silver & Gold Mines Ltd. drill results are detailed in separate news releases and these releases are available on our website at www.avino.com and on our SEDAR profile at www.sedar+.com.
This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including the mineral resource estimate for the Company’s Avino Property, including La Preciosa, located near Durango in west-central Mexico (the “Avino Property”) with an effective date of October 16, 2023 and can be viewed within Avino’s latest technical report dated February 5, 2024 for the Pre-feasibility Study and references to Measured, Indicated Resources, and Proven and Probable Mineral Reserves referred to in this press release. This information and these statements, referred to herein as “forward-looking statements” are made as of the date of this document. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the estimated amount and grade of mineral reserves and mineral resources, including the cut-off grade; (ii) estimates of the capital costs of constructing mine facilities and bringing a mine into production, of operating the mine, of sustaining capital, of strip ratios and the duration of financing payback periods; (iii) the estimated amount of future production, both ore processed and metal recovered and recovery rates; (iv) estimates of operating costs, life of mine costs, net cash flow, net present value (NPV) and economic returns from an operating mine; and (v) the completion of the full Technical Report, including a Preliminary Economic Assessment, and its timing. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “envisages”, “assumes”, “intends”, “strategy”, “goals”, “objectives” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.
Cautionary note to U.S. Investors concerning estimates of Mineral Reserves and Mineral Resources
All reserve and resource estimates reported by Avino were estimated in accordance with the Canadian National Instrument 43-101 and the Canadian Institute of Mining, Metallurgy and Petroleum (“CIM”) Definition Standards. The U.S. Securities and Exchange Commission (“SEC”) now recognizes estimates of “measured mineral resources,” “indicated mineral resources” and “inferred mineral resources” and uses new definitions of “proven mineral reserves” and “probable mineral reserves” that are substantially similar to the corresponding CIM Definition Standards. However, the CIM Definition Standards differ from the requirements applicable to US domestic issuers. US investors are cautioned not to assume that any “measured mineral resources,” “indicated mineral resources,” or “inferred mineral resources” that the Issuer reports are or will be economically or legally mineable. Further, “inferred mineral resources” are that part of a mineral resource for which quantity and grade are estimated on the basis of limited geologic evidence and sampling. Mineral resources which are not mineral reserves do not have demonstrated economic viability.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
La Palma, CA October 27, 2025 –(PR.com)– Liminatus Pharma, Inc. (NASDAQ: LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets.
Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws. The subscription funds are expected to be remitted following the submission and effectiveness of a registration statement relating to the resale of the shares. Both parties aim to finalize and execute the definitive agreements in November 2025.
In addition to the equity investment, beginning in mid-November this year and subject to definitive agreements being signed, Liminatus and CTG plan to commence discussions for further strategic cooperation, including potential future digital bond financing programs.
“We believe that this MOU marks the beginning of a long-term partnership with CTG,” said Chris Kim, Chief Executive Officer of Liminatus Pharma. “The equity financing would strengthen our financial foundation.”
About Liminatus Pharma, Inc. (NASDAQ: LIMN)
Liminatus Pharma is a clinical-stage immuno-oncology company pioneering next-generation therapeutics, including its proprietary CD47-blockade antibody IBA101, designed to overcome the limitations of first-generation immune therapies in solid tumors.
About Capital Trust Group Limited (CTG)
Capital Trust Group is a New Zealand-based investment management and digital finance firm managing large-scale institutional and blockchain-enabled financing programs across healthcare, energy, and infrastructure sectors. CTG has the privilege of having General Chavalit Yongchaiyudh, the 22nd Prime Minister of Thailand, as one of its shareholders and an honorable advisor.
CTG Contact
Wasupit Wises, Director — wises@ctgprime.com, +66 61 7722142
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected equity investment, timing of definitive agreements, potential future digital bond programs, and anticipated financial and strategic benefits. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those described herein. Factors that may cause such differences include, among others, the ability to finalize and execute definitive agreements, regulatory and market conditions, and the availability of financing. Liminatus undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Contact Information:
Liminatus Pharma, Inc
Chris Kim
213-273-5453 Contact via Email
www.liminatuspharma.com
Plano, TX October 27, 2025 –(PR.com)– PLANO, Texas – Lemond Nutrition, a registered dietitian private practice in Plano, Texas, is joining MYOR, a nationwide community of registered dietitian practices committed to improving health outcomes through innovative technology and evidence-based care.
Established in 2009, Lemond Nutrition has cultivated a reputation with families and healthcare providers for its scientific and personalized approach for nutrition for prevention and treatment of health conditions. Becoming a part of MYOR is an exciting new opportunity that will allow for the same exceptional and caring care, alongside improved digital tools and engagement with better insurance networks. “This partnership creates the opportunity for Lemond Nutrition to continue to provide the trusted and personalized nutrition care the community has depended on, now with enhanced technology and expanded accessibility,” said Angela Lemond, the previous co-owner of Lemond Nutrition.
Jeff and Angela Lemond, who are transitioning from ownership of the practice, will still maintain an equity interest in the company and will work with MYOR to share the best practices and quality that Lemond Nutrition has spent the past 16 years developing and employing in the nutrition field. Angela Lemond also remains a registered dietitian in the practice while shifting some energies to her counseling practice, Lemond Therapy. “We look forward to continuing to care for all of Lemond Nutrition’s patients in the Dallas area with the same high quality care that Lemond Nutrition has delivered for many years,” said Dr. Ariel Katz, CEO of MYOR.
About Lemond Nutrition
Established in 2009, Lemond Nutrition is a team of registered dietitian nutritionists devoted to improving lives through practical, evidence-based nutrition counseling. The practice serves individuals and families across all stages of life, empowering sustainable health and well-being.
About MYOR
MYOR is a national network connecting registered dietitians and dietitian practices through innovative technology and data-driven care. By integrating personalized nutrition strategies into broader healthcare systems, MYOR helps improve outcomes and is advancing the future of nutrition-based medicine.
Media Contact:
Michael Brandwein, PhD
Co-Founder
MYOR
5900 Balcones Drive
Austin, TX
512-253-1679
michael@myorcare.com
myorthrive.com
Contact Information:
MYOR
Michael Brandwein
512-253-1679 Contact via Email
myorthrive.com
Phoenix, AZ October 27, 2025 –(PR.com)– North Mountain Brewery is excited to announce their Executive Chef Jackie Abril-Carlile will be inducted into Les Disciples Escoffier USA this coming Tuesday, October 28, 2025. www.northmountainbrewing.com
This is an incredibly prestigious honor and North Mountain Brewery is proud of Chef Jackie’s major accomplishment.
To be inducted within Les Disciples Escoffier International, Chef Jackie was supported and endorsed by two distinguished sponsors: Chef Kareen Linton, 1st Delegate – Tampa Chapter and Chef Sebastien Giannini, President East Coast Chapter.
Chef Jackie has built a remarkable career as a Chef Instructor at Auguste Escoffier School of Culinary Arts, where she inspires and mentors the next generation of chefs. She holds a Bachelor’s in Culinary Arts and Service Management and Double Master’s Degrees in Business and Secondary Education. She is fluent in American Sign Language and was a teacher at the Phoenix School for the Deaf.
At North Mountain Brewery, Chef Jackie brings her background in classical French cooking to elevate the traditional pub food fare. Customer favorites include Pizza, Burgers, Lumpia, and similar MediterrAsian foods. She works closely with the Head Brewer, Rob Berkner, to highlight their Craft Beer in food items such as their house-made pizza dough.
Congratulations and Cheers to Chef Jackie Abrile-Carlile on her achievement and the well-deserved award.
Contact Information:
North Mountain Brewing Company
Candy Froogzo
602-861-5999 Contact via Email
www.northmountainbrewing.com
Robert Berkner- 602.380.7027
LAKE TAHOE, Nev., Oct. 26, 2025 / PRZen / Phinge® Corporation, creator of the upcoming Netverse® hardware-verified technology platform, today detailed a proposal for federal agencies to dramatically reduce waste, fraud, and abuse (WFA) in programs such as Medicare, Medicaid, Social Security and others.
The Netverse platform will be accessible exclusively through patented, proprietary hardware. The proposal highlights how the platform’s core principle of “one verified user to one Netverse phone or device” could eliminate impersonation and fake recipients, moving beyond the reactive systems currently used by many government agencies.
This proactive approach will prevent WFA before it can occur, protecting taxpayer dollars and safeguarding the integrity of vital government services.
“The federal government loses between $233 billion and $521 billion annually to fraud, according to GAO’s government-wide estimates based on data from fiscal years 2018 through 2022. Additionally, federal improper payment estimates have totaled about $2.8 trillion since FY 2003—and the actual amount may be significantly higher because this is based on a small number of programs that report these numbers.
Using the above GAO low-end statistics and using the example of 100 million people in the U.S. receiving government benefits and accounting for a per phone price of $1,000.00 and adding 100% for program administration costs, the phones would be paid for in fraud reduction in less than 1 year.
This does not even factor in federal improper payment estimates. If improper payments were made through Netverse phones or devices to recipients, they have the ability to be timely clawed back.
Eliminating impersonation and fake recipients A cornerstone of the Netverse platform will be its hardware-based verification system, which will permanently bind a user’s verified identity to their individual Netverse phone or device. This will create a verifiable, tamper-resistant link between an individual and their access to services
Permanent identity binding: Unlike software-based identity checks that can be spoofed or bypassed, Netverse’s hardware-level verification will ensure that a recipient of government benefits is a real, unique individual. The principle of “one user, one phone” would make it impossible for fraudsters to create multiple fake accounts to claim benefits.
Proactive identity protection: The current systems used by government agencies primarily monitor for fraudulent activity after a user’s data has been compromised. In contrast, the Netverse approach will prevent identity fraud from the outset by requiring a verified, hardware-bound identity for all participants. This will stop fraudsters from using stolen Social Security numbers or other personal data to claim benefits illegally.
Secure benefit delivery: With each recipient tied to a single, verified Netverse hardware device, benefit payments can be routed securely and transparently. The system would eliminate the possibility of payments being diverted to fake or fraudulent accounts, as every financial transaction would originate from a verified user on their dedicated Netverse hardware.
Secure and transparent data access: By replacing fragmented, app-based systems with a unified, verified ecosystem, Netverse will provide a secure and reliable platform for government agencies to interact with beneficiaries. Every interaction is tied to a verified identity, creating a clear audit trail and significantly reducing opportunities for malfeasance.
Government agencies could purchase from Phinge and implement a plan where all recipients of government benefits could receive an authorized Phinge device for free or at a reduced cost.
If they did this, phone recipients could reap additional benefits through their interactions with Netverse in the form of same-as-cash rewards to spend dollar-for-dollar throughout Netverse and all its businesses and third-party platforms. This would include using their earned rewards to pay for their internet access and monthly phone bills through Phinge.
In addition, 1% of all gross dollars that would be spent through these phones or devices throughout Netverse would be donated by Phinge to local charities selected by users.
Phinge including its Netverse solution is designed to not only align with existing government regulations regarding data privacy, but will go above and beyond, by allowing its users to own and control their own data. This will provide a secure and powerful new tool for user privacy while protecting taxpayer dollars.
Phinge was founded and through Netverse® is being developed to disrupt today’s outdated App technologies, including the App-store duopoly, by partnering with and giving its users and businesses ownership and control of their data, enhanced privacy and a better overall mobile experience including their ability to monetize it.
Phinge through its upcoming patented Netverse App-less technology platform with proprietary AI, will be a better, safer, verified and rewarding alternative platform and technology for users and third party businesses and developers to today’s App stores, operating systems and ecosystems of Apple, Google and Android.
LSEG and Anthropic collaborate to make more financial data accessible to Claude for Enterprise customers
LONDON, UK / ACCESS Newswire / October 27, 2025 / LSEG today announced a collaboration with Anthropic granting access to data licensed through LSEG products, like Workspace and Financial Analytics, for Claude customers. This will be available through Anthropic’s expanded Claude for Financial Services offering – launched today.
This is the latest milestone in LSEG’s AI strategy – LSEG Everywhere – which is delivering trusted licensed data to scale AI in financial services. The unparalleled depth, breadth, and quality of LSEG’s AI-ready content and taxonomies includes datasets stretching back over decades.
LSEG Everywhere includes the adoption of MCP and involves recent partnerships with enterprise grade AI applications and data platforms including Microsoft, Rogo, Snowflake and Databricks.
AI powered by LSEG’s licensed AI-ready content in financial workflows LSEG is granting access to data licensed through its products like Workspace and Financial Analytics so customers can automate financial analysis. LSEG’s AI-ready content will be accessible through MCP in a phased rollout, starting with LSEG Financial Analytics. Following this first release, LSEG will grant Claude users access to more licensed AI-ready content, with initial capabilities launching later this month and additional data categories to follow.
LSEG is setting the standard for secure, scalable AI in financial services with its open, LLM-agnostic, and infrastructure-oriented partnership approach enabling workflows through open protocols such as MCP. This helps customers to minimise cost and custom engineering and accelerate deployment times.
Through this collaboration, LSEG and Anthropic are also embedding mutual lead generation processes. Claude for Financial Services customers can augment their existing data with licences for LSEG’s flagship Workspace solution. LSEG is partnering with Workspace customers to secure licensed enterprise access to Claude.
Ron Lefferts, Co-Head, Data & Analytics at LSEG, said: “LSEG has a long-established reputation for our open, partnership approach and meeting our customers wherever their workflows are taking place. Secure, enterprise grade AI applications, such as Claude, and open standards like MCP are expanding the opportunities for LSEG to build deep partnerships with customers.
“With Claude for Financial Services, our customers can now access LSEG’s unmatched financial data and insights to power and scale agentic AI directly within their workflows.”
Nicholas Lin, Head of Product, Financial Services at Anthropic, said: “Combining Claude’s intelligence with data and context offers real value. With LSEG’s trusted data, Claude is able to summarize earnings calls, scan diligence materials, trigger agentic workflows and surface instant market signals – all with enterprise-grade controls.”
MCP integration accelerates deployment, simplifies interoperability and expands LSEG reach This collaboration builds on LSEG’s adoption of the Model Context Protocol (MCP), the open standard pioneered by Anthropic. LSEG’s MCP server, live in the Claude MCP Partner Directory from Monday 27 October, ensures secure, seamless access to LSEG’s licensed AI-ready content.
The Claude MCP Partner Directory provides Enterprise customers with a single point of access to a range of trusted partners and, via MCP, full interoperability with their own AI systems and other third-party applications.
LSEG Everywhere – Our AI Strategy Artificial intelligence is transforming financial markets. With our unmatched data, infrastructure, and partnerships, LSEG is uniquely positioned at the forefront of this change. Find out more here
Investors Peregrine Riviere / Chris Turner – Investor Relations ir@lseg.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
